Share Email Print

Proceedings Paper

Transurethral microwave therapy of the prostate
Author(s): Zbigniew P. Petrovich; Stuart Boyd M.D.; Filip Ameye M.D.; Luc Baert M.D.
Format Member Price Non-Member Price
PDF $17.00 $21.00

Paper Abstract

Benign prostatic hyperplasia (BPH) is a common disease entity. The treatment of choice for BPH is surgery. Non-surgical treatment is of importance primarily in BPH patients who require therapeutic intervention but have relative contraindications to surgery. Non-surgical treatment currently under investigation include: medical therapy with alpha blockers, balloon dilatation and hypertheimia (HT). HT in BPH patients has been most frequently applied with microwaves at 915 MHz, utilizing a transrectal or transurethral (TUHT) approach. TUHT used in poor surgical risk BPH patients has been uniformly well tolerated without major toxicity. This treatment was applied on an outpatient basis without sedation or anesthesia. A major and long lasting objective and subjective benefit consistently exceeded 70% in patients with lateral lobes hyperplasia. In those patients with predominance of median lobe or median bar enlargement the efficacy was only 30%. TIJHT has shown to be very effective also in BPH patients presenting with urinary retention. A strong correlation between applied temperature and response was demonstrated. More work is needed to optimize TUHT technique and treatment schedule. A phase III prospective randomized trial is needed to define the role of this emerging treatment modality in BPH patients.

Paper Details

Date Published: 1 June 1992
PDF: 6 pages
Proc. SPIE 1643, Laser Surgery: Advanced Characterization, Therapeutics, and Systems III, (1 June 1992); doi: 10.1117/12.137338
Show Author Affiliations
Zbigniew P. Petrovich, Univ. of Southern California (United States)
Stuart Boyd M.D., Univ. of Southern California (United States)
Filip Ameye M.D., Univ. of Leuven (Belgium)
Luc Baert M.D., Univ. of Leuven (Belgium)

Published in SPIE Proceedings Vol. 1643:
Laser Surgery: Advanced Characterization, Therapeutics, and Systems III
R. Rox Anderson M.D., Editor(s)

© SPIE. Terms of Use
Back to Top
Sign in to read the full article
Create a free SPIE account to get access to
premium articles and original research
Forgot your username?